What we do Vivo Bio Tech Ltd is a full-service Contract Research Organization offering drug development and discovery services, including preclinical studies, pharmacology, and bioanalytical research to pharmaceutical and biotech companies globally. |
Founded in 1,987 |
Market share Largest breeder and distributor of specific pathogen free (SPF) lab animals in India and pioneering provider of rodent models and biological research services. |
Problem solved Provides comprehensive preclinical research infrastructure and expertise to advance pharmaceutical drug discovery and development. |
Top clients or who we serve Pharmaceutical and biotech companies worldwide; B2B focus serving drug development needs. |
Key management Mr. M. Kalyan Ram (Whole Time Director), Dr. Sankaranarayanan Alangudi (Whole Time Director), Mr. Sri Kalyan Kompella (Whole Time Director & CFO). |
Our journey and innovations Started as lab animal breeder in 1987, evolved into a full-service CRO with strategic partnerships (Taconic, Cyagen) and expanded services into genomic technologies and pharmacokinetic studies. |
Where we operate Primarily India; international clients across pharmaceutical and biotech sectors globally. |
Top products or what we offer In vitro and in vivo toxicology studies, pharmacology, pharmacokinetics, genotoxicity screening, analytical and bioanalytical services, SPF lab animal breeding and distribution. |
Top brands Authorized distributor for Special Diets Services (UK) in India; collaboration with Taconic Biosciences and Cyagen Biosciences for advanced animal models and genomic services. |
Raw materials needed SPF laboratory animals including rodents and guinea pigs; lab animal diets and reagents for biological assays. |
Raw materials supplier Taconic Biosciences, Elm Hill Labs (USA), Special Diets Services (UK), Cyagen Biosciences. |
Recurring vs cyclical contribution Revenue mainly recurring from ongoing research services and animal model breeding contracts. |
Our industry position Premier CRO in India with market-leading SPF animal breeding and comprehensive preclinical research services. |
Financial highlights FY2023-24 revenue approximately Rs 46.9 crores; net profit Rs 7.28 crores; maintaining stable profitability. |
Geographical revenue split Majority revenue from Indian operations with global pharmaceutical clients. |
Order book - |
Whats driving growth Growing pharmaceutical R&D outsourcing, expansion in genomic technologies, and strategic partnerships. |
Our future plans Ramp up investments for portfolio expansion and enhance service offerings in preclinical research and ADME/PK-PD studies. |
Our green promise Focus on health, safety, and environmental excellence integrated into business operations. |
Our people and values Cultivates ethical and transparent work culture emphasizing integrity and accountability. |
Key challenges ahead Managing regulatory changes, sustaining quality standards, and competitive marketplace pressures. |
Interesting facts India's largest breeder of SPF lab animals; pioneer in commercial SPF guinea pig distribution. |
Risks and strategy Mitigates operational risks through strong governance, quality management systems, and strategic collaborations. |
